These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 11368382)
61. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation. Min CK; Kim DW; Lee JW; Min WS; Kim CC Acta Haematol; 2000; 104(4):185-92. PubMed ID: 11279309 [TBL] [Abstract][Full Text] [Related]
63. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. Tayebi H; Tiberghien P; Ferrand C; Lienard A; Duperrier A; Cahn JY; Lapierre V; Saas P; Kuentz M; Blaise D; Hervé P; Robinet E; Bone Marrow Transplant; 2001 Jan; 27(2):167-75. PubMed ID: 11281386 [TBL] [Abstract][Full Text] [Related]
64. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells]. de Gast GC; Verdonck LF; van Kempen-Harteveld ML; Gerritsen H; Dekker AW Ned Tijdschr Geneeskd; 1986 May; 130(19):868-71. PubMed ID: 3520348 [No Abstract] [Full Text] [Related]
66. [Allogeneic bone marrow transplantation in the treatment of leukemia--a preliminary report]. Chen YC; Wang CH; Lin DT; Lui PT; Cheng AL; Liu TW; Tsay W; Tien HF; Liu MC; Chuu WM Taiwan Yi Xue Hui Za Zhi; 1987 May; 86(5):490-6. PubMed ID: 3305776 [No Abstract] [Full Text] [Related]
67. Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients. Iravani M; Tavakoli E; Babaie MH; Ashouri A; Khatami F; Ghavamzadeh A Exp Clin Transplant; 2010 Mar; 8(1):66-73. PubMed ID: 20199374 [TBL] [Abstract][Full Text] [Related]
68. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation]. Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007 [No Abstract] [Full Text] [Related]
69. [Current status of allogeneic-peripheral blood stem cell transplantation and the possibility for unrelated donor-peripheral blood stem cell transplantation]. Shinagawa K; Harada M Rinsho Ketsueki; 1998 May; 39(5):342-4. PubMed ID: 9637881 [No Abstract] [Full Text] [Related]
70. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM). Michallet M; Tanguy ML; Socié G; Thiébaut A; Belhabri A; Milpied N; Reiffers J; Kuentz M; Cahn JY; Blaise D; Demeocq F; Jouet JP; Michallet AS; Ifrah N; Vilmer E; Molina L; Michel G; Lioure B; Cavazzana-Calvo M; Pico JL; Sadoun A; Guyotat D; Attal M; Curé H; Bordigoni P; Sutton L; Buzyn-Veil A; Tilly M; Keoirruer N; Feguex N Br J Haematol; 2000 Feb; 108(2):400-7. PubMed ID: 10691873 [TBL] [Abstract][Full Text] [Related]
71. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases]. Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932 [TBL] [Abstract][Full Text] [Related]
72. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821 [TBL] [Abstract][Full Text] [Related]
74. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Eapen M; Horowitz MM; Klein JP; Champlin RE; Loberiza FR; Ringdén O; Wagner JE J Clin Oncol; 2004 Dec; 22(24):4872-80. PubMed ID: 15520055 [TBL] [Abstract][Full Text] [Related]
75. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
78. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001 [TBL] [Abstract][Full Text] [Related]
79. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Basara N; Blau WI; Kiehl MG; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA Transplant Proc; 1998 Dec; 30(8):4087-9. PubMed ID: 9865306 [No Abstract] [Full Text] [Related]